Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review
- PMID: 35086660
- DOI: 10.1016/j.jacc.2021.12.002
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review
Abstract
Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart disease, with complex phenotypic and genetic expression and natural history, affecting both genders and many races and cultures. Prevalence is 1:200-1:500, largely based on the disease phenotype with imaging, inferring that 750,000 Americans may be affected by HCM. However, cross-sectional data show that only a fraction are clinically diagnosed, suggesting under-recognition, with most clinicians exposed to small segments of the broad disease spectrum. Highly effective HCM management strategies have emerged, altering clinical course and substantially lowering mortality and morbidity rates. These advances underscore the importance of reliable HCM diagnosis with echocardiography and cardiac magnetic resonance. Family screening with noninvasive imaging will identify relatives with the HCM phenotype, while genetic analysis recognizes preclinical sarcomere gene carriers without left ventricular hypertrophy, but with the potential to transmit disease. Comprehensive initial patient evaluations are important for reliable diagnosis, accurate portrayal of HCM and family history, risk stratification, and distinguishing obstructive versus nonobstructive forms.
Keywords: cardiac magnetic resonance; echocardiography; electrocardiogram; hypertrophic cardiomyopathy; hypertrophy.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures Dr Desai has served as a consultant for Bristol Myers Squibb, Medtronic, and Caristo Diagnostics. Dr Martin Maron has served as a steering committee member for Cytokinetics, Imbria Pharmaceuticals, and Takeda Pharmaceuticals; and has received research grant support from Takeda Pharmaceuticals. Dr Sherrid has served as a consultant for Celltrion, Inc. Dr Rowin has received research grant support from Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
